- Home
- LI vs KYMR Comparison
LI vs KYMR Comparison
Compare LI & KYMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LI | KYMR |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Auto Manufacturing | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.5B | 10.6B |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | LI | KYMR |
|---|---|---|
| Price | $11.72 | $115.20 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 26 |
| Target Price | $19.66 | ★ $107.72 |
| AVG Volume (30 Days) | ★ 2.6M | 592.1K |
| Earning Date | 05-28-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $39,211,000.00 |
| Revenue This Year | $18.98 | $10.61 |
| Revenue Next Year | $22.72 | $8.17 |
| P/E Ratio | $29.50 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.44 | $53.20 |
| 52 Week High | $26.83 | $130.05 |
Technical Indicators
Market Signals| Indicator | LI | KYMR |
|---|---|---|
| Relative Strength Index (RSI) | 45.04 | 58.10 |
| Support Level | N/A | $110.64 |
| Resistance Level | $12.56 | $128.95 |
| Average True Range (ATR) | 0.28 | 4.44 |
| MACD | -0.01 | 0.17 |
| Stochastic Oscillator | 28.19 | 84.42 |
Price Performance
Historical ComparisonAbout LI Li Auto Inc.
Li Auto is one of China's leading new energy vehicle manufacturers. Founded in 2015, the company designs, develops, manufactures, and sells premium smart NEVs with a particular focus on family size premium SUVs and MPVs. Li Auto started volume production of its first model—the Li One, an SUV that is a premium plug-in electric vehicle- in November 2019. Besides PHEVs, its product portfolio now extends to EVs that are fully battery-powered, reaching a wide audience. It has sold over 400,000 NEVs in 2025, accounting for about 3% of China's passenger NEV market.
About KYMR Kymera Therapeutics Inc.
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.